CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-07). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.7.
Verdict No. 2356 · Search date 2026-08-07 · Methodology v0.7

CPAP,
does it really help with Prevention of atrial-fibrillation recurrence after pulmonary-vein isolation?

30-Second Summary
D
Evidence Grade D · 30 · Safety caution
Post-ablation recurrence was 57% in both groups, but adherence and precision remain limiting
CPAP commonly causes mask discomfort, nasal or oral dryness, and air leak, often requiring mask or pressure adjustment. Prescribed sleep-apnea treatment should not be stopped solely because of this atrial-fibrillation result.
What the
research shows
The grade is D with 30 points. Among patients with paroxysmal atrial fibrillation and obstructive sleep apnea, recurrence after pulmonary-vein isolation was 57% in both the CPAP and standard-care groups. The reported odds ratio was 1.0 (95% CI 0.4 to 2.4), P=1.00, over 12 months after ablation. This was an ablation study, not a post-cardioversion study.
What the
ads claim
The study does not prove benefit with fully sustained use, but it also does not justify saying the device itself can never prevent recurrence.
*

Useful facts when choosing a product

  • The population had pulmonary-vein isolation, not merely cardioversion.
  • Mean nightly use was 3.9±1.5 hours before and 4.3±1.9 hours after ablation.
  • Verdict 1179 is F with 9 points for recurrent cardiovascular events, verdict 1212 is B with 72 points for sleepiness and quality of life, and verdict 1764 is C with 56 points for blood pressure in resistant hypertension. This verdict has a different endpoint.
Gap Measurement · Verdict 2356 · D 30
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Hunt and colleagues randomized 109 CPAP-tolerant patients with paroxysmal atrial fibrillation and sleep apnea to CPAP or standard care. After pre-ablation exclusions, 83 underwent pulmonary-vein isolation: 37 versus 46. An implanted loop recorder identified episodes longer than two minutes after a three-month blanking period. Twelve-month recurrence was 57% in each group; the paper reported an odds ratio, not a risk ratio. Rhythm assessment was blinded, although participant blinding was impossible. The Caples cardioversion trial addressed a different treatment stage and was not counted as replication of the post-ablation question.

02

Why this is classified as D (30)

A small trial with substantial post-randomization exclusion was null but imprecise, giving D with 30 points.

Counterpoint. CPAP may still be indicated for sleep-apnea symptom treatment independently of the atrial-fibrillation endpoint.

Rejudgment record. Cross-check applied — Null single small randomized post-ablation trial with wide confidence interval, substantial post-randomization exclusion, and limited nightly exposure

Scoring profile behind this grade
EndpointHHard endpoint - actual events such as death
ReplicationR1Single confirmatory trial
IndependenceI1Mixed funding sources
Effect sizeE0Null
PrecisionC0The confidence interval leaves room for benefit

The scoring table and the verdict agree (D).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Prevention of AF recurrence after ablationDTwelve-month recurrence was 57% in both groups.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Study 1Open-label randomized trial with blinded rhythm assessment46South-Eastern Norway Regional Health Authority, Research Council of Norway, and an unrestricted ResMed grant; device support from ResMed and MedtronicAF recurrence longer than two minutes after a three-month blanking periodAt 12 months, 57% versus 57%; OR 1.0 (95% CI 0.4 to 2.4), P=1.00.Pivotal direct trial
Study 2Randomized post-cardioversion trial25Manufacturer funding not confirmed in the accessible reportAF recurrence within one year after cardioversion25% in both groups; population and treatment stage differed from post-ablation care.Indirect evidence from a different treatment stage
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-08-07).

Hunt TE, Traaen GM, Aakerøy L, et al. Effect of continuous positive airway pressure therapy on recurrence of atrial fibrillation after pulmonary vein isolation in patients with obstructive sleep apnea: a randomized controlled trial. Heart Rhythm. 2022;19(9):1433-1441. DOI: 10.1016/j.hrthm.2022.06.016.
checked
Caples SM, Mansukhani MP, Friedman PA, Somers VK. The impact of continuous positive airway pressure treatment on the recurrence of atrial fibrillation post cardioversion: a randomized controlled trial. Int J Cardiol. 2019;278:133-136. DOI: 10.1016/j.ijcard.2018.11.100.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-07 · Corrections: none

Cite this verdict

CPAP x atrial-fibrillation recurrence after ablation Evidence Grade D card
[Chamgap] CPAP x atrial-fibrillation recurrence after ablation — Evidence Grade D·30. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/cpap-atrial-fibrillation-recurrence-after-ablation/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.